The Migraine Drugs Market is expected to reach $15.54 billion by 2032, growing at a CAGR of 11.34%. The US market is set to reach $5.80 billion by 2032, fueled by advanced treatments and high healthcare spending. CGRP inhibitors are revolutionizing migraine therapy, leading to more effective relief for patients.
The Preventive treatment segment dominates the global migraine drugs market with a 61.06% share. Injectables, such as CGRP monoclonal antibodies, lead the market with a 68.76% share. Pediatric migraine cases hold a 60.40% market share, while geriatrics show the highest CAGR of 12.43%.
North America dominates the market with a 45.60% share, while Asia Pacific is the fastest-growing region with an 8.28% CAGR. AbbVie’s Qulipta and Teva’s biosimilar to Ajovy are recent developments in the migraine drugs market. The report also covers environmental compliance, supply chain disruptions, and patient demographics. The global market for migraine drugs is projected to reach $5.4 billion by 2026, with a CAGR of 3.7%. Factors driving growth include increasing prevalence of migraines and advancements in drug development. Triptans are the most commonly prescribed class of migraine drugs, accounting for a significant market share.
A new report by S&S Insider provides in-depth analysis and insights into the migraine drugs market. The report covers market dynamics, key players, competitive landscape, and future trends. It also includes detailed profiles of major companies, market segmentation, and regional analysis. The report aims to help businesses make informed decisions and stay ahead in the competitive market.
S&S Insider is a leading market research and consulting agency, providing clients with up-to-date market data and insights. With a focus on delivering accurate and reliable information, the company uses various research techniques such as surveys, video talks, and focus groups. The goal is to empower clients with the knowledge they need to navigate the ever-changing market landscape and make strategic decisions.
Read more at GlobeNewswire: Migraine Drugs Market Projected to Surpass USD 15.54